Pathology of malignant mesothelioma

Histopathology

Volumn 30, Issue 5, 1997, Pages 403-418

  Attanoos, R L ^a   Gibbs, A R ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

adenomatoid tumour; asbestos; malignant mesothelioma; multicystic mesothelioma; peritoneum; pleura; well differentiated papillary mesothelioma

Indexed keywords

ASBESTOS;

ADENOMATOID TUMOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; TUMOR BIOPSY;

EID: 0030903808     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1997.5460776.x     Document Type: Review

References (120)

1. Enzinger FM, Weiss SW. Soft Tissue Tumours, 3rd edn. St Louis: Mosby, 1995; 787-819.
2. Battifora H, McCaughey WTE. Tumours and pseudotumours of the serosal membranes. In: Atlas of Tumour Pathology, 3rd series, fascicle 15. Washington, DC: Armed Forces Institute of Pathology, 1995; 15-88.
3. Kannerstein M, Churg J. Peritoneal mesothelioma. Hum. Pathol. 1977; 8; 83-94.
4. Roggli VL. Pericardial mesothelioma after exposure to asbestos. N. Engl. J. Med. 1981; 304; 1045.
5. Jones MA, Young RH, Scully RE. Malignant mesothelioma of the tunica vaginalis: A clinicopathologic analysis of 11 cases with review of the literature. Am. J. Surg. Pathol. 1995; 19; 815-825.
6. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J. Ind. Med. 1960; 17; 260-271.
7. Selikoff IJ, Churg J, Hammond EC. Relation between asbestos exposure and mesothelioma. N. Engl. J. Med. 1965; 272; 560-565.
8. Acheson ED, Gardner MJ, Pippard EC et al. Mortality of two groups of women who manufactured gas masks from chrysotile and crocidolite asbestos: a 40-year follow-up. Br. J. Ind. Med. 1982; 39; 344-348.
9. Peto J, Hodgson J, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345; 535-539.
10. Executive Office of Population Censuses and Surveys/Health and Safety. Occupational Health Decennial Supplement edition. London, HM Stationery Office, 1995.
11. McDonald JC, McDonald AD. Epidemiology of mesothelioma. In: Liddell D, Miller K, eds. Mineral Fibres and Health. Boca Raton: CRC Press, 147-168.
12. Damhuis RAM, Planteydt HT. Mesothelioma. Lancet 1995; 345; 1233-1234.
13. De Klerk NH, Armstrong BK. The epidemiology of asbestos and mesothelioma. In: Malignant Mesothelioma. Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, eds. New York: Hemisphere Publishing Company, 223-250.
14. Selcuk ZT, Coplu L, Kalyoncu AF, Sahin AA, Baris YI. Malignant pleural mesothelioma due to environmental mineral fibre exposure in Turkey: analysis of 135 cases. Chest 1992; 102; 790-796.
15. Gibbs AR, Jones JSP, Pooley FD, Griffiths DM. Non occupational mesotheliomas. In: Bignon J, Peto J, Saracci R, eds. Non occupational exposure to mineral libres. IARC. Sci. Bull. 1989; 90; 219-228.
16. Gibbs AR. Role of asbestos and other fibres in the development of diffuse malignant mesothelioma. Thorax 1990; 45; 649-654.
17. Acheson ED, Gardner MJ, Bennett C. Mesothelioma in a factory using amosite and chrysotile asbestos. Lancet 1981; 2; 1403-1406.
18. McDonald AD, McDonald JC, Pooley FD. Mineral fibre content of lung in mesothelial tumours in North America. Ann. Occup. Hyg. 1982; 26; 417-422.
19. Lanphear BP, Buncher CR. Latent period of malignant mesothelioma of occupational origin. J.O.M. 1992; 7; 718-722.
20. Greengard O, Head JF, Chahinian AP, Goldberg SL. Enzyme pathology of human mesotheliomas. J.N.C.I. 1987; 78; 617-622.
21. Peto J, Seidman H, Selikoff IJ. Mesothelioma mortality in asbestos workers: implications for carcinogenesis and risk assessment. Br. J. Cancer 1982; 45; 123-135.
22. Doll R, Peto J. Effects on health of exposure to asbestos. In: Asbestos, London, Her Majesty Stationery Office.
23. Pooley FD, Ranson DL. Comparison of the results of asbestos fibre dust counts in lung tissue obtained by analytical electron microscopy and light microscopy. J. Clin. Pathol. 1976; 39; 313-317.
24. Timbrell V, Griffiths DM, Pooley FD. Possible biological importance of fibre diameters of South Africa amphiboles. Nature 1971; 232; 55-56.
25. McDonald JC, Armstrong B, Doell D, McCaughey WTE, McDonald AD, Sebastien P. Mesothelioma and asbestos fibre type - evidence from lung tissue analysis. Cancer 1989; 63; 1544-1556.
26. Boutin C, Dumortier P, Rey F, Villat JR, De Vuyst P. Black spots concentrate oncogenic fibres in the parietal pleura. Am. J. Resp. Med. 1996; 153; 444-449.
27. Gibbs AR, Stephens M, Griffiths DM, Blight BJN, Pooley FD. Fibre distribution in the lungs and pleura of subjects with asbestos-related diffuse pleural fibrosis. Br. J. Ind. Med. 1991; 48; 762-770.
28. Masse R, Sebastien P, Monchaux G, Bignon J. Experimental demonstration of the penetration of fibres into the gastrointestinal tract. In: Wagner JC, ed. Biological effects of mineral fibres. Wagner JC, Lyon: IARC Scientific Publications, 321-328.
29. Hourihane D. A biopsy series of mesotheliomata, and attempts to identify asbestos within some of the tumours. Ann. N.Y. Acad. Sci. 1965; 132; 647-673.
30. Auerbach O, Conston AS, Garfinkel L et al. Presence of asbestos bodies in organs other than the lung. Chest 1980; 77; 133.
31. Wagner JC, Berry G, Skidmore JW, Timbrell V. The effects of the inhalation of asbestos in rats. Br. J. Cancer 1974; 29; 252-269.
32. Zalma R, Bonneau L, Jaurand MC, Guignard J, Pezerat H. Formation of oxy-radicals by oxygen reduction arising from the surface activity of asbestos. Can. J. Med. 1987; 65; 2338-2341.
33. Goodlick LA, Kane AB. Role of reactive oxygen metabolites in crocidolite toxicity to mouse macrophages. Cancer Res. 1986; 46; 5558-5566.
34. Goodlick LA, Pietras LA, Kane AB. Evaluation of the causal relationship between crocidolite asbestos-induced lipid peroxidation and toxicity to macrophages. Am. Rev. Respir. Dis. 1989; 139; 1265-1273.
35. Fletjer WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumour suppressor genes. Genes, Chrom. Cancer 1989; 1; 148-154.
36. Tiainen M, Tammilehto L, Mattson K, Knuutila S. Non-random chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet. Cytogenet. 1988; 33; 251-274.
37. Gerwin BI, Lechner JF, Reddel RR et al. Comparison of production of transforming growth factor-B and platelet derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 1987; 47; 6180-6184.
38. Leveck MA, Somers ANA, Moore LL, Gerwin BI, Lechner JF. Dissimilar peptide growth factors can induce normal human mesothelial cell multiplication. In Vitro Cell Dev. Biol. 1988; 24; 1077-1082.
39. Underhill C. CD44: the hyaluronan receptor. J. Cell Sci. 1992; 103; 293-298.
40. Bielefeldt-Ohmann H, Jarnick GA, Fitzpatrick DR. Molecular pathobiology and immunology of malignant mesothelioma. J. Pathol. 1996; 178; 569-378.
41. Heinz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and c-jun protoncogene expression by asbestos. Proc. Natl. Acad. Sci. USA, 1993; 90; 3299-3303.
42. Suzuki Y, Weston A, Ashley R. Immunocytochemical analysis of oncoproteins and growth factors in human malignant mesothelioma. Oncol. Rep. 1995; 2; 897-902.
43. Newman RH. Fine biogenic silica fibres in sugarcane: a possible hazard. Ann. Occup. Hyg. 1986; 30; 365-370.
44. Shannon VR, Besbitt JC, Libshitz HI. Malignant pleural mesothelioma after radiation therapy for breast cancer. Cancer 1995; 76; 437-441.
45. Gilks B, Hegedus C, Freeman H, Fratkin L, Churg A. Malignant peritoneal mesothelioma after remote abdominal irradiation. Cancer 1988; 61; 2019-2021.
46. Maurer R, Egloff B. Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 1975; 36; 1381-1385.
47. Stey C, Landolt-Weber U, Vetter W, Sauter C, Marinek B. Malignant peritoneal mesothelioma after thorotrast exposure. Am. J. Clin. Oncol. 1995; 18: 313-517.
48. Sanders CL, Jackson TA. Induction of mesotheliomas and sarcomas from 'hot spots' of 239 plutonium dioxide activity. Health Phys. 1972; 22; 755-759.
49. Allison AC, Chesterman FC, Baron S. Induction of tumours in adult hamsters with simian virus-40. J. Natl. Cancer Inst. 1967; 38; 567-577.
50. Jensen F, Koprowski H, Pagano JS, Ponten J, Ravdin RG. Autologous and homologous implantation of human cells transformed in vitro by SV 40. J. Natl. Cancer Inst. 1964; 32; 917-925.
51. Carbone M, Pass HI, Rizzo P et al. Simian Virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994; 9; 1781-1790.
52. Pepper C, Jasani B, Navabi H, Wynford-Thomas D, Gibbs AR. Simian Virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Thorax 1996; 51; 1074-1076.
53. Hillerdal G, Berg J. Malignant mesothelioma secondary to chronic inflammation and old scars: two new cases and review of the literature. Cancer 1984; 55; 1968-1972.
54. Riddell RH, Goodman MJ, Moossa AR. Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. Cancer 1981; 48; 134-139.
55. Gold C. A primary mesothelioma involving the recto-vaginal septum and associated with beryllium. J. Path. Bact. 1967; 93; 435-442.
56. Hammar SP, Bockus D, Remington F, Freedman S, Lazerte G. Familial mesothelioma: A report of two families. Hum. Pathol. 1989; 20; 107-112.
57. Otte KE, Sigstaard TI, Kjaerulff J. Malignant mesothelioma: Clustering in the family producing asbestos cement in their home. Br. J. Ind. Med. 1990; 47; 10-13.
58. Dawson A, Gibbs AR, Browne K, Pooley FD, Griffiths DM. Familial mesothelioma: details of 17 cases with histopathologic findings and mineral analysis. Cancer 1992; 70; 1185-1187.
59. Crotty TB, Myers JL, Katzenstein AL, Tazelaar HD, Swensen SJ, Churg A. Localized malignant mesothelioma: a clinicopathologic and flow cytometric study. Am. J. Surg. Pathol. 1994; 18; 357-363.
60. England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumours of the pleura. A clinicopathological review of 223 cases. Am. J. Surg. Pathol. 1989; 13; 640-658.
61. Dervan PA, Tobin B, O'Connor M. Solitary (localised) fibrous mesothelioma: evidence against mesothelial cell origin. Histopathology 1986; 10; 867-875.
62. Young RH, Clement PB, McCaughey WTE. Solitary fibrous tumours (fibrous mesotheliomas) of the peritoneum: a report of three cases. Arch. Pathol. Lab. Med. 1990; 114; 495-495.
63. Browne K, Smither WJ. Asbestos-related mesothelioma: factors discriminating pleural and peritoneal sites. Br. J. Ind. Med. 1983; 40; 145-152.
64. Mayall FG, Gibbs AR. Malignant peritoneal mesothelioma giving rise to multiple intestinal polyps. Histopathology 1991; 18; 480-482.
65. Daya D, McCaughey WTE. Well differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases. Cancer 1990; 65; 292-296.
66. Weiss SW, Tavassoli FA. Multicystic mesothelioma: an analysis of pathologic findings and biologic behaviour in 37 cases. Am. J. Surg. Pathol. 1988; 12; 737-746.
67. Nascimento GA, Keeney GL, Fletcher CDM. Deciduoid peritoneal mesothelioma. An unusual phenotype affecting young females. Am. J. Surg. Pathol. 1994; 18; 439-445.
68. Taxy JB, Battifora H, Oyasu R. Adenomatoid tumours: a light microscopic, histochemical and ultrastructural study. Cancer 1974; 34; 306-316.
69. Nicholson CP, Donahue JH, Thompson GB, Lewis JE. A study of metastatic cancer found during inguinal hernia repair. Cancer 1992; 69; 3008-3011.
70. Sarma DP, Weilbaecher TG. Adenocarcinoma of the rete testis. J. Surg. Oncol. 1985; 30; 67-71.
71. Young RH, Scully RE. Testicular and paratesticular tumours and tumour-like lesions of ovarian common epithelial and mullerian types. A report of four cases and review of the literature. Am. J. Clin. Oncol. 1986; 86; 146-152.
72. Dessy E, Pietra GG. Pseudomesotheliomatous carcinoma of the lung. An immunohistochemical and ultrastructural study of 3 cases. Cancer 1991; 68; 1747-1753.
73. Mayall FG, Gibbs AR. Pleural and pulmonary carcinosarcomas. J. Pathol. 1992; 167; 305-311.
74. Taylor DR, Page W, Hughes D, Varghese G. Metastatic renal cell carcinoma mimicking pleural mesothelioma. Thorax 1987; 42; 901-902.
75. Attanoos RL, Dallimore NS, Gibbs AR. Primary epithelioid haemangioendothelioma of the peritoneum: An unusual mimic of mesothelioma. Histopathology 1997; 30; 375-577.
76. Tavassoli FA, Norris HJ. Peritoneal leiomyomatosis (leiomyomatosis peritonealis disseminata): a clinicopathologic study of 20 cases with ultrastructural observations. Int. J. Gynaecol. Pathol. 1982; 1; 59-74.
77. Gibbs AR, Whimster WF. Tumours of the lung and pleura. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. Volume 1. Edinburgh: Churchill Livingstone, 127-150.
78. Mayall FG, Gibbs AR. The histology and immunohistochemistry of small cell mesothelioma. Histopathology 1992; 20; 47-51.
79. Yousem SA, Hochholzer L. Malignant mesotheliomas with osseous and cartilaginous differentiation. Arch. Pathol. Lab. Med. 1987; 111; 62-66.
80. Wilson GE, Hasleton PS, Chatterjee AK. Desmoplastic malignant mesothelioma: A review of 17 cases. J. Clin. Pathol. 1992; 45; 295-298.
81. Henderson DW, Attwood HD, Constance TJ, Shilkin KB, Steele RH. Lymphohistiocytoid mesothelioma: A rare lymphomatoid variant of sarcomatoid mesothelioma. Ultrastruct. Pathol. 1988; 12; 367-384.
82. Goepel JR. Benign papillary mesothelioma of peritoneum: A histological, histochemical and ultrastructural study of six cases. Histopathology 1981; 5; 21-30.
83. Barbera V, Rubino M. Papillary mesothelioma of the tunica vaginalis. Cancer 1957; 10; 183-189.
84. Burrig KF, Pfitzer P, Hort W. Well differentiated papillary mesothelioma of the peritoneum: A borderline mesothelioma. Report of 2 cases and review of the literature. Virchows Arch. (A) 1990; 417; 443-447.
85. Katsube Y, Mukai K, Silverberg SG. Cystic mesothelioma of the peritoneum: A report of live cases and review of the literature. Cancer 1982; 50; 1615-1620.
86. Ball NJ, Urbanski SJ, Green FHY, Kieser TH. Pleural multicystic mesothelial proliferation: The so-called multicystic mesothelioma. Am. J. Surg. Pathol. 1990; 14; 375-378.
87. Ross MJ, Welch WR, Scully RE. Multiocular peritoneal inclusion cysts (so-called cystic mesothelioma). Cancer 1989; 64; 1336-1346.
88. Talerman A, Montera JR, Chilcote RR, Okagaki T. Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature. Am. J. Surg. Pathol. 1985; 9; 73-80.
89. Craig JR, Hart WR. Extragenital adenomatoid tumour. Evidence for the mesothelial theory of origin. Cancer 1979; 433; 1678-1679.
90. Young RH, Silva EG, Scully RE. Ovarian and juxtaovarian adenomatoid tumours: a report of six cases. Int. J. Gynaecol. Pathol. 1991; 10; 364-371.
91. Kaplan MA, Tazelaar HD, Hayashi T, Schroer KR, Travis WD. Adenomatoid tumours of the pleura. Am. J. Surg. Pathol. 1996; 20; 1219-1223.
92. Wagner JC, Munday DE, Harrington JS. Histochemical demonstration of hyaluronic acid in pleural mesotheliomas. J. Path. Bact. 1962; 84; 73-78.
93. Leong AS-YM, Stevens MW, Mukherjee TM. Malignant mesothelioma: cytologic diagnosis with histologie, immunohistochemical, and ultrastructural correlation. Semin. Diagn. Pathol. 1992; 9; 141-150.
94. Roggli VL, Kolbeck J, Sanfilippo F. Pathology of human mesothelioma. Aetiology and diagnostic considerations. Pathol. Annu. 1987; 22; 91-131.
95. Gibbs AR, Harach R, Wagner JC, Jasani B. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. Thorax 1985; 40; 91-95.
96. Ordonez NG. The immunohistochemical diagnosis of mesothelioma. Am. J. Surg. Pathol. 1989; 13; 276-291.
97. Wick MR, Loy T, Mills SE et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical, ultrastructural and immunohistochemical study of 103 cases. Hum. Pathol. 1990; 21; 759-766.
98. Soosay GN, Griffiths M, Papadaki L, Happerfield L, Bobrow L. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. J. Pathol. 1991; 163; 299-305.
99. Otis CN, Carter D, Cole S, Battifora H et al. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases. Am. J. Surg. Pathol. 1987; 11; 445-456.
100. Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am. J. Surg. Pathol. 1984; 8; 277-279.
101. Sheibani K, Esteban JM, Bailey A, Battifora H, Weiss LM. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum. Pathol. 1992; 23; 107-116.
102. Dejmek A. Methods to improve the diagnostic accuracy of malignant mesothelioma. Resp. Med. 1996; 90; 191-199.
103. Robb JA. Mesothelioma versus adenocarcinoma: false positive CEA and Leu-M1 staining due to hyaluronic acid (Letter). Hum. Pathol. 1989; 20; 400.
104. Khoury N, Raju U, Crissman JD, Zarbo RJ, Greenwald KA. A comparative immunohistochemical study of peritoneal and ovarian serous tumours, and mesotheliomas. Hum. Pathol. 1990; 21; 811-819.
105. Bollinger DJ, Wick MR, Dehner LP et al. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma. A histochemical and immunohistochemical comparison. Am. J. Surg. Pathol. 1989; 13; 659-670.
106. Collins CL, Ordonez NG, Schaefer R, Cook CD. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am. J. Pathol. 1992; 141; 827-833.
107. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of mesothelioma. Histopathology 1996; 29; 209-215.
108. Walts AE, Said JW, Shintaku IP. Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: Immunocytochemical and ultrastructural localisation in benign and malignant cells. Diagn. Cytol. Pathol. 1987; 3; 41-49.
109. Kafiri G, Thomas DM, Shepherd NA et al. p53 expression is common in malignant mesotheliomas. Histopathology 1992; 21; 531-554.
110. Mayall FG, Goddard H, Gibbs AR. An assessment of p53 immunostaining in the distinction between benign and malignant mesothelial proliferation using formalin fixed paraffin sections. J. Pathol. 1993; 168: 337-381.
111. Ramael M, Buysse C, Van den Bossche J, Segers K, Van Marck E. Immunoreactivity for the B-chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J. Pathol. 1992; 167; 1-4.
112. Ramael M, Van den Bossche J, Buysse C et al. Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody [SB-1. J. Pathol. 1992; 167; 5-8.
113. Burns TR, Greenberg D, Mace ML, Johnson EH. Ultrastructural diagnosis of epithelial malignant mesothelioma. Cancer 1985; 56; 2036-2040.
114. Coleman M, Henderson DW, Muhkerjee TM. The ultrastructural pathology of malignant pleural mesothelioma. Pathol. Annu. 1989; 24; 303-353.
115. Donna A, Betta PG, Bellingeri D, Marchesini A. New marker for mesothelioma: an immunoperoxidase study. J. Clin. Pathol. 1986; 39; 961-968.
116. Donna A, Betta PG, Jones JSP. Verification of the histological diagnosis of malignant mesothelioma in relation to the binding of an anti-mesothelial cell antibody. Cancer 1989; 63; 1331-1336.
117. Attanoos RL, Webb R, Gibbs AR. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Histopathology 1997; 30; 260-263.
118. Azumi N, Underhill CB, Kagan E, Sheibani K. A novel biotinylated probe specific for hyalurate: its diagnostic value in diffuse malignant mesothelioma. Am. J. Surg. Pathol. 1992; 16; 116-121.
119. Amin KM, Litzky LA, Smythe WR et al. Wilm's tumour 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am. J. Pathol. 1995; 146; 344-356.
120. Doglioni C, Dei Tos AP, Laurino L et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am. J. Surg. Pathol. 1996; 20; 1037-1046.